TAASTRUP, Denmark--(BUSINESS WIRE)--FluimediX, a point-of-care diagnostic company, announced today that it has received funding for the continued development of the NanoCycler™, a diagnostic platform for the measurement of relevant genetic mutations in patients. The proceeds of this financing round will be dedicated to developing a diagnostic test for Warfarin™ metabolism. The investment round was led by SEED Capital Denmark, a leading early stage investor managing more than € 200 million in total assets. Existing shareholders also participated in the financing. The size of the round was not disclosed.
